Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML
The B-cell lymphoma 2 inhibitor venetoclax (VEN) in combination with hypomethylating agents has been approved for first-line treatment of patients with acute myeloid leukemia (AML) ineligible for intensive treatment. VEN-containing treatment strategies may also be effective in relapsed/refractory (R...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
17 January 2025
|
| In: |
Blood advances
Year: 2025, Jahrgang: 9, Heft: 2, Pages: 375-385 |
| ISSN: | 2473-9537 |
| DOI: | 10.1182/bloodadvances.2024013086 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1182/bloodadvances.2024013086 Verlag, kostenfrei, Volltext: https://ashpublications.org/bloodadvances/article/9/2/375/517882/Venetoclax-based-salvage-therapy-as-a-bridge-to 
|
| Verfasserangaben: | Julia M. Unglaub, Richard F. Schlenk, Jan Moritz Middeke, Stefan W. Krause, Sabrina Kraus, Hermann Einsele, Michael Kramer, Sven Zukunft, Joseph Kauer, Simon Renders, Elena Katelari, Christoph Schliemann, Caroline Pabst, Thomas Luft, Peter Dreger, Christoph Röllig, Martin Bornhäuser, Carsten Müller-Tidow, and Tim Sauer, for the Study Alliance Leukemia |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1937138569 | ||
| 003 | DE-627 | ||
| 005 | 20250930114512.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250926s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/bloodadvances.2024013086 |2 doi | |
| 035 | |a (DE-627)1937138569 | ||
| 035 | |a (DE-599)KXP1937138569 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Unglaub, Julia Marie |e VerfasserIn |0 (DE-588)1247235157 |0 (DE-627)1780861508 |4 aut | |
| 245 | 1 | 0 | |a Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML |c Julia M. Unglaub, Richard F. Schlenk, Jan Moritz Middeke, Stefan W. Krause, Sabrina Kraus, Hermann Einsele, Michael Kramer, Sven Zukunft, Joseph Kauer, Simon Renders, Elena Katelari, Christoph Schliemann, Caroline Pabst, Thomas Luft, Peter Dreger, Christoph Röllig, Martin Bornhäuser, Carsten Müller-Tidow, and Tim Sauer, for the Study Alliance Leukemia |
| 264 | 1 | |c 17 January 2025 | |
| 300 | |b Illustrationen | ||
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 26.09.2025 | ||
| 520 | |a The B-cell lymphoma 2 inhibitor venetoclax (VEN) in combination with hypomethylating agents has been approved for first-line treatment of patients with acute myeloid leukemia (AML) ineligible for intensive treatment. VEN-containing treatment strategies may also be effective in relapsed/refractory (R/R) AML; however, comparative studies with conventional therapies for fit patients as a bridge-to-transplant strategy are limited. Using propensity score matching (PSM), we compared 37 patients with R/R AML, who received VEN-based salvage therapy as bridge to allogeneic hematopoietic stem cell transplantation (allo-HCT), with 90 patients from the German Study Alliance Leukemia AML registry, who were treated with non-VEN-containing salvage therapy according to their treating physician’s choice (TPC). The overall response rate among VEN patients was higher than the TPC control cohort (62% vs 42%; P = .049). Overall, 73% of VEN-treated patients vs 63% of TPC patients were bridged to allo-HCT (P = .41). After a median follow-up of 34.3 months for the VEN and 21.0 months for the TPC cohort, the median overall survival (OS) were 15.8 months (95% confidence interval [CI], 10.6 to not evaluable) and 10.5 months (95% CI, 6.8-19.6; P = .15), respectively. PSM revealed a trend toward improved OS for VEN patients (hazard ratio, 0.70; 95% CI, 0.41-1.22; P = .20). Median event-free survival was significantly longer in the VEN cohort (8.0 months) than the TPC cohort (3.7 months; P = .006). Our data suggest that VEN-based salvage therapy is a safe and effective bridge to allo-HCT for this difficult-to-treat AML patient population. | ||
| 700 | 1 | |a Schlenk, Richard Friedrich |d 1965- |e VerfasserIn |0 (DE-588)129025380 |0 (DE-627)387778004 |0 (DE-576)297454102 |4 aut | |
| 700 | 1 | |a Middeke, Jan Moritz |e VerfasserIn |4 aut | |
| 700 | 1 | |a Krause, Stefan W. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kraus, Sabrina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Einsele, Hermann |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kramer, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zukunft, Sven |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kauer, Joseph |d 1992- |e VerfasserIn |0 (DE-588)1161466134 |0 (DE-627)102475524X |0 (DE-576)50654382X |4 aut | |
| 700 | 1 | |a Renders, Simon |e VerfasserIn |0 (DE-588)1207477311 |0 (DE-627)1693807467 |4 aut | |
| 700 | 1 | |a Katelari, Elena |e VerfasserIn |0 (DE-588)1377563103 |0 (DE-627)1937138763 |4 aut | |
| 700 | 1 | |a Schliemann, Christoph |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pabst, Caroline |d 1981- |e VerfasserIn |0 (DE-588)136164668 |0 (DE-627)577203819 |0 (DE-576)284653667 |4 aut | |
| 700 | 1 | |a Luft, Thomas |e VerfasserIn |0 (DE-588)1078976309 |0 (DE-627)839996969 |0 (DE-576)452120659 |4 aut | |
| 700 | 1 | |a Dreger, Peter |e VerfasserIn |0 (DE-588)1028891881 |0 (DE-627)732699894 |0 (DE-576)376320966 |4 aut | |
| 700 | 1 | |a Röllig, Christoph |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bornhäuser, Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Müller-Tidow, Carsten |d 1968- |e VerfasserIn |0 (DE-588)1015101798 |0 (DE-627)705330230 |0 (DE-576)351197893 |4 aut | |
| 700 | 1 | |a Sauer, Tim |d 1981- |e VerfasserIn |0 (DE-588)138282013 |0 (DE-627)601099516 |0 (DE-576)307058166 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood advances |d Washington, DC : American Society of Hematology, 2016 |g 9(2025), 2 vom: Jan., Seite 375-385 |h Online-Ressource |w (DE-627)873588312 |w (DE-600)2876449-3 |w (DE-576)48043249X |x 2473-9537 |7 nnas |a Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML |
| 773 | 1 | 8 | |g volume:9 |g year:2025 |g number:2 |g month:01 |g pages:375-385 |g extent:11 |a Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML |
| 856 | 4 | 0 | |u https://doi.org/10.1182/bloodadvances.2024013086 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://ashpublications.org/bloodadvances/article/9/2/375/517882/Venetoclax-based-salvage-therapy-as-a-bridge-to |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250926 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 138282013 |a Sauer, Tim |m 138282013:Sauer, Tim |d 910000 |d 910100 |e 910000PS138282013 |e 910100PS138282013 |k 0/910000/ |k 1/910000/910100/ |p 19 |y j | ||
| 998 | |g 1015101798 |a Müller-Tidow, Carsten |m 1015101798:Müller-Tidow, Carsten |d 910000 |d 910100 |e 910000PM1015101798 |e 910100PM1015101798 |k 0/910000/ |k 1/910000/910100/ |p 18 | ||
| 998 | |g 1028891881 |a Dreger, Peter |m 1028891881:Dreger, Peter |d 910000 |d 910100 |e 910000PD1028891881 |e 910100PD1028891881 |k 0/910000/ |k 1/910000/910100/ |p 15 | ||
| 998 | |g 1078976309 |a Luft, Thomas |m 1078976309:Luft, Thomas |d 910000 |d 910100 |d 50000 |e 910000PL1078976309 |e 910100PL1078976309 |e 50000PL1078976309 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 14 | ||
| 998 | |g 136164668 |a Pabst, Caroline |m 136164668:Pabst, Caroline |d 910000 |d 910100 |e 910000PP136164668 |e 910100PP136164668 |k 0/910000/ |k 1/910000/910100/ |p 13 | ||
| 998 | |g 1377563103 |a Katelari, Elena |m 1377563103:Katelari, Elena |d 910000 |d 910100 |e 910000PK1377563103 |e 910100PK1377563103 |k 0/910000/ |k 1/910000/910100/ |p 11 | ||
| 998 | |g 1207477311 |a Renders, Simon |m 1207477311:Renders, Simon |d 910000 |d 910100 |e 910000PR1207477311 |e 910100PR1207477311 |k 0/910000/ |k 1/910000/910100/ |p 10 | ||
| 998 | |g 1161466134 |a Kauer, Joseph |m 1161466134:Kauer, Joseph |d 910000 |d 910100 |e 910000PK1161466134 |e 910100PK1161466134 |k 0/910000/ |k 1/910000/910100/ |p 9 | ||
| 998 | |g 129025380 |a Schlenk, Richard Friedrich |m 129025380:Schlenk, Richard Friedrich |d 910000 |d 910100 |e 910000PS129025380 |e 910100PS129025380 |k 0/910000/ |k 1/910000/910100/ |p 2 | ||
| 998 | |g 1247235157 |a Unglaub, Julia Marie |m 1247235157:Unglaub, Julia Marie |d 910000 |d 910100 |e 910000PU1247235157 |e 910100PU1247235157 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1937138569 |e 4776621304 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Julia M. Unglaub, Richard F. Schlenk, Jan Moritz Middeke, Stefan W. Krause, Sabrina Kraus, Hermann Einsele, Michael Kramer, Sven Zukunft, Joseph Kauer, Simon Renders, Elena Katelari, Christoph Schliemann, Caroline Pabst, Thomas Luft, Peter Dreger, Christoph Röllig, Martin Bornhäuser, Carsten Müller-Tidow, and Tim Sauer, for the Study Alliance Leukemia"]},"id":{"doi":["10.1182/bloodadvances.2024013086"],"eki":["1937138569"]},"recId":"1937138569","physDesc":[{"noteIll":"Illustrationen","extent":"11 S."}],"person":[{"display":"Unglaub, Julia Marie","family":"Unglaub","given":"Julia Marie","role":"aut"},{"display":"Schlenk, Richard Friedrich","family":"Schlenk","given":"Richard Friedrich","role":"aut"},{"display":"Middeke, Jan Moritz","role":"aut","given":"Jan Moritz","family":"Middeke"},{"display":"Krause, Stefan W.","role":"aut","given":"Stefan W.","family":"Krause"},{"display":"Kraus, Sabrina","family":"Kraus","given":"Sabrina","role":"aut"},{"display":"Einsele, Hermann","given":"Hermann","role":"aut","family":"Einsele"},{"family":"Kramer","role":"aut","given":"Michael","display":"Kramer, Michael"},{"display":"Zukunft, Sven","family":"Zukunft","given":"Sven","role":"aut"},{"given":"Joseph","role":"aut","family":"Kauer","display":"Kauer, Joseph"},{"given":"Simon","role":"aut","family":"Renders","display":"Renders, Simon"},{"family":"Katelari","given":"Elena","role":"aut","display":"Katelari, Elena"},{"family":"Schliemann","given":"Christoph","role":"aut","display":"Schliemann, Christoph"},{"family":"Pabst","given":"Caroline","role":"aut","display":"Pabst, Caroline"},{"family":"Luft","role":"aut","given":"Thomas","display":"Luft, Thomas"},{"role":"aut","given":"Peter","family":"Dreger","display":"Dreger, Peter"},{"display":"Röllig, Christoph","family":"Röllig","given":"Christoph","role":"aut"},{"role":"aut","given":"Martin","family":"Bornhäuser","display":"Bornhäuser, Martin"},{"display":"Müller-Tidow, Carsten","role":"aut","given":"Carsten","family":"Müller-Tidow"},{"display":"Sauer, Tim","given":"Tim","role":"aut","family":"Sauer"}],"relHost":[{"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 27.04.21"],"title":[{"title":"Blood advances","title_sort":"Blood advances"}],"origin":[{"publisher":"American Society of Hematology","dateIssuedDisp":"[2016]-","publisherPlace":"Washington, DC"}],"disp":"Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AMLBlood advances","physDesc":[{"extent":"Online-Ressource"}],"recId":"873588312","id":{"zdb":["2876449-3"],"eki":["873588312"],"issn":["2473-9537"]},"part":{"text":"9(2025), 2 vom: Jan., Seite 375-385","extent":"11","issue":"2","pages":"375-385","volume":"9","year":"2025"},"name":{"displayForm":["American Society of Hematology"]},"pubHistory":["Vol. 1, iss. 1 (November 2016)-"]}],"origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"17 January 2025"}],"title":[{"title":"Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML","title_sort":"Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML"}],"note":["Gesehen am 26.09.2025"],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"}} | ||
| SRT | |a UNGLAUBJULVENETOCLAX1720 | ||